Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials-Reference-Cited by-同舟云学术

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

Published:2013-11 Issue:9 Volume:1 Page:714-727
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Franciosi Lui G,Diamant Zuzana,Banner Katharine H,Zuiker Rob,Morelli Nicoletta,Kamerling Ingrid M C,de Kam Marieke L,Burggraaf Jacobus,Cohen Adam F,Cazzola Mario,Calzetta Luigino,Singh Dave,Spina Domenico,Walker Michael J A,Page Clive P

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference35 articles.

1. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma;Chowdhury;N Engl J Med,2011

2. Pharmacology and therapeutics of bronchodilators;Cazzola;Pharmacol Rev,2012

3. Phosphodiesterase inhibitors in the treatment of inflammatory diseases;Page;Handb Exp Pharmacol,2011

4. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors;de Boer;Br J Pharmacol,1992

5. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease;Banner;Br J Pharmacol,2009

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensifentrine approval: A milestone in the treatment of COPD;Pulmonary Pharmacology & Therapeutics;2024-12

2. Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease;Trends in Pharmacological Sciences;2024-09

3. Ensifentrine: First Approval;Drugs;2024-08-28

4. Prevalence and Management of Chronic Obstructive Pulmonary Disease in the Gulf Countries with a Focus on Inhaled Pharmacotherapy;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2024-08-01

5. Reply to Gan et al., to Calzetta et al., and to Poor;American Journal of Respiratory and Critical Care Medicine;2024-01-15